Publications

STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma

Download PDF
Resource: STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma

.

Related Articles

Immune Composition and Immunotherapy Outcomes of Mesothelioma with BAP1, CDKN2A, MTAP, and NF2 Alterations

Link
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy

Link